Hussman Strategic Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Hussman Strategic Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.56M	Buy	210,000 +126,000	+150%	+$2.01M	0.82%	18
2026 Q1	$1.24M	Sell	84,000 -21,000	-20%	-$307K	0.27%	169
2025 Q4	$1.67M	Sell	105,000 -21,000	-17%	-$298K	0.4%	111
2025 Q3	$1.39M	Sell	126,000 -231,000	-65%	-$2.52M	0.3%	153
2025 Q2	$3.02M	Buy	357,000 +147,000	+70%	+$1.18M	0.69%	47
2025 Q1	$1.69M	Buy	+210,000	New	+$1.7M	0.41%	98

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hussman Strategic Advisors's AUPH Position: Q2 2026 in Review

Hussman Strategic Advisors increased its Aurinia Pharmaceuticals (AUPH) stake by 150% in Q2 2026, buying an estimated $2.01M and bringing the position to 210,000 shares worth $3.56M. The position accounts for 0.82% of the portfolio, ranked #18.

Hussman Strategic Advisors first reported a position in AUPH in Q1 2025 and has held it in 6 quarters since. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Hussman Strategic Advisors held 210,000 shares of Aurinia Pharmaceuticals worth $3.56M as of Q2 2026.
Hussman Strategic Advisors bought 126,000 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $2.01M.
Aurinia Pharmaceuticals made up 0.82% of Hussman Strategic Advisors's portfolio in Q2 2026, its #18 holding.
Hussman Strategic Advisors first reported a position in Aurinia Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.